Infection-Associated Flares in Systemic Lupus Erythematosus
Authors:
- Giuseppe A. RamirezGRGiuseppe A. Ramirez
- Chiara CalabreseCCChiara Calabrese
- Marta SecciMSMarta Secci
- Luca MoroniLMLuca Moroni
- Gabriele D. GallinaGGGabriele D. Gallina
- Giovanni BenantiGBGiovanni Benanti
- Enrica P. BozzoloEBEnrica P. Bozzolo
- Marco Matucci-CerinicMMMarco Matucci-Cerinic
- Lorenzo DagnaLDLorenzo Dagna
Open Access
Abstract
Systemic lupus erythematosus (SLE) is characterised by generalised immune dysfunction, including infection susceptibility. Infection-associated flares (IAFs) are common and might rapidly self-resolve, paralleling infection resolution, but their specific clinical phenotype is poorly understood. Therefore, we screened 2039 consecutive visits and identified 134 flares, defined as a loss of the lupus low disease activity state (LLDAS), from 1089 visits at risk spanning over multiple follow-up years, yielding an average yearly LLDAS deterioration rate of 17%. Thirty-eight IAFs were isolated from the total flares and were mostly related to bacterial and herpesvirus infections. When compared to other flares (OFs; n = 98), IAFs showed no milder patterns of organ involvement and similar rates of long-term damage accrual, as estimated by conventional clinimetrics. Arthritis in IAFs was more severe than that in OFs [median (interquartile range) DAS-28 2.6 (2.3–4.1) vs. 2.0 (1.6–2.7); p = 0.02]. Viral IAFs were characterised by atypically lower levels of anti-DNA antibodies (p < 0.001) and possibly abnormally high complement levels when compared to flares of different origin. These data suggest that IAFs are of comparable or even higher severity than OFs and may subtend distinct pathophysiological mechanisms that are poorly tackled by current treatments. Further research is needed to confirm these data.Keywords
This publication has 89 references indexed in Scilit:
- Systemic Lupus ErythematosusJAMA, 2024
- Histone‐Specific CD4+ T Cell Plasticity in Active and Quiescent Systemic Lupus ErythematosusArthritis & Rheumatology, 2024
- Active vaccination campaign to increase seasonal influenza vaccination coverage: a monocenter experience in a cohort of Italian patients with systemic autoimmune diseasesClinical Rheumatology, 2022
- Four Systemic Lupus Erythematosus Subgroups, Defined by Autoantibodies Status, Differ Regarding HLA‐DRB1 Genotype Associations and Immunological and Clinical ManifestationsACR Open Rheumatology, 2021
- Gradual Glucocorticosteroid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus ErythematosusACR Open Rheumatology, 2021
- Rheumatology university faculty opinion on coronavirus disease-19 (COVID-19) vaccines: the vaXurvey study from EgyptRheumatology International, 2021
- Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosusArthritis Care & Research, 2011
- Employment and disability issues in systemic lupus erythematosus: A reviewArthritis Care & Research, 2008
- Epitope spreading in systemic lupus erythematosus: Identification of triggering peptide sequencesArthritis & Rheumatism, 2002
- Antibody reactivity to the hres‐1 endogenous retroviral element identifies a subset of patients with systemic lupus erythematosus and overlap syndromesArthritis & Rheumatism, 1995